Inovio Pharmaceuticals, Inc. (INO)

Inovio Pharmaceuticals is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q4 2022 Earnings Call Transcript

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q4 2022 Earnings Call Transcript March 1, 2023 Operator: Good afternoon, and welcome to the Inovio Pharmaceuticals Fourth Quarter 2022 Financial Results Confe...

INOVIO to Present at the Oppenheimer 33rd Annual Healthcare Conference

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today ...

Inovio Pharmaceuticals (INO) Q4 2022 Earnings Call Transcript

Good afternoon, and thank you for joining the Inovio 2022 fourth quarter and full year financial results conference call. Joining me on today's call are Dr. Jackie Shea, president and CEO and Dr. Mic...

Inovio Pharmaceuticals (INO) Reports Q4 Loss, Lags Revenue Estimates

Inovio (INO) delivered earnings and revenue surprises of -31.25% and 72.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...

INOVIO Reports Fourth Quarter and Full Year 2022 Financial Results and Clinical Highlights

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today ...

Disclaimer: The data contained in Super Surge website is not necessarily real-time nor accurate and may differ from the actual market data. Prices, volumes, ratios, charts and indicators are indicative and not appropriate for trading purposes. Super Surge doesn't bear any responsibility for any trading losses you might incur as a result of using this data.